Tenax Therapeutics to Participate in the Guggenheim SMID Cap Biotech Conference
Tenax Therapeutics (TENX), a Phase 3 development-stage pharmaceutical company focused on cardiovascular and pulmonary diseases, has announced its participation in the upcoming Guggenheim SMID Cap Biotech Conference. The event will take place in New York from February 5-6, 2025.
Company President & CEO Chris Giordano will participate in a fireside chat on February 5, 2025, at 3:00 pm ET. The presentation will be available via webcast, accessible through the company's investor relations webpage. Additionally, Tenax management will be conducting one-on-one investor meetings during the conference, which can be arranged through Guggenheim representatives.
Tenax Therapeutics (TENX), una compagnia farmaceutica in fase di sviluppo clinico di Fase 3 focalizzata sulle malattie cardiovascolari e polmonari, ha annunciato la sua partecipazione alla prossima Guggenheim SMID Cap Biotech Conference. L'evento si svolgerà a New York dal 5 al 6 febbraio 2025.
Il Presidente e CEO dell'azienda Chris Giordano parteciperà a un incontro informale il 5 febbraio 2025, alle 15:00 ET. La presentazione sarà disponibile tramite webcast, accessibile attraverso la pagina web delle relazioni con gli investitori dell'azienda. Inoltre, la direzione di Tenax condurrà incontri individuali con gli investitori durante la conferenza, che possono essere organizzati attraverso i rappresentanti di Guggenheim.
Tenax Therapeutics (TENX), una compañía farmacéutica en fase de desarrollo clínico de Fase 3 centrada en enfermedades cardiovasculares y pulmonares, ha anunciado su participación en la próxima Guggenheim SMID Cap Biotech Conference. El evento se llevará a cabo en Nueva York del 5 al 6 de febrero de 2025.
El Presidente y CEO de la empresa Chris Giordano participará en una charla informal el 5 de febrero de 2025, a las 3:00 pm ET. La presentación estará disponible a través de una transmisión en línea, accesible a través de la página web de relaciones con inversionistas de la compañía. Además, la dirección de Tenax realizará reuniones individuales con inversionistas durante la conferencia, las cuales pueden ser organizadas a través de los representantes de Guggenheim.
Tenax Therapeutics (TENX)는 심혈관 및 호흡기 질환에 중점을 둔 3상 개발 단계의 제약 회사로, 다가오는 Guggenheim SMID Cap Biotech Conference에 참여할 것이라고 발표했습니다. 이 행사는 2025년 2월 5일부터 6일까지 뉴욕에서 개최됩니다.
회사의 회장 겸 CEO인 Chris Giordano는 2025년 2월 5일 오후 3시에 진행될 예정인 파이어사이드 채팅에 참석합니다. 발표는 회사의 투자자 관계 웹 페이지를 통해 접근 가능한 웹캐스트로 제공됩니다. 또한 Tenax 경영진은 컨퍼런스 동안 투자자와의 일대일 미팅을 진행하며, 이는 Guggenheim 대표를 통해 조정될 수 있습니다.
Tenax Therapeutics (TENX), une entreprise pharmaceutique en phase de développement de Phase 3 axée sur les maladies cardiovasculaires et pulmonaires, a annoncé sa participation à la prochaine Guggenheim SMID Cap Biotech Conference. L'événement se déroulera à New York du 5 au 6 février 2025.
Le Président et PDG de l'entreprise Chris Giordano participera à une discussion informelle le 5 février 2025 à 15h00 ET. La présentation sera disponible par le biais d'un webinaire, accessible via la page des relations investisseurs de l'entreprise. De plus, la direction de Tenax organisera des réunions individuelles avec les investisseurs pendant la conférence, qui peuvent être arrangées par l'intermédiaire des représentants de Guggenheim.
Tenax Therapeutics (TENX), ein pharmazeutisches Unternehmen in der klinischen Entwicklungsphase 3, das sich auf kardiovaskuläre und pulmonale Erkrankungen konzentriert, hat seine Teilnahme an der bevorstehenden Guggenheim SMID Cap Biotech Conference angekündigt. Die Veranstaltung findet vom 5. bis 6. Februar 2025 in New York statt.
Der Präsident und CEO des Unternehmens, Chris Giordano, wird am 5. Februar 2025 um 15:00 Uhr ET an einem informellen Gespräch teilnehmen. Die Präsentation wird über einen Webcast verfügbar sein, der über die Investor Relations-Webseite des Unternehmens zugänglich ist. Darüber hinaus wird das Management von Tenax während der Konferenz Einzelgespräche mit Investoren führen, die über die Vertreter von Guggenheim organisiert werden können.
- None.
- None.
CHAPEL HILL, N.C., Jan. 31, 2025 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (Nasdaq: TENX) (“Tenax Therapeutics” or the “Company”), a Phase 3, development-stage pharmaceutical company focused on identifying, developing and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical need, today announced that the Company will participate in a fireside chat at the Guggenheim SMID Cap Biotech Conference, which is taking place from February 5-6, 2025, in New York, NY.
| Details of presentation: | |
| Format: | Fireside Chat |
| Participant: | Chris Giordano, President & Chief Executive Officer |
| Date and time: | February 5, 2025, at 3:00 pm ET |
| Location: | Webcast: Click here |
Tenax Therapeutics’ management will also participate in one-on-one investor meetings. To request a one-on-one meeting at the conference, please contact your Guggenheim representative.
The live and archived webcast of the presentation will be accessible from the Company’s investor relations webpage.
About Tenax Therapeutics
Tenax Therapeutics, Inc. is a Phase 3, development-stage pharmaceutical company focused on developing and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical need. The Company owns global rights to develop and commercialize levosimendan, which it has prioritized in the near term. Tenax Therapeutics also may resume developing its unique oral formulation of imatinib. For more information, visit www.tenaxthera.com. Tenax Therapeutics’ common stock is listed on The Nasdaq Stock Market LLC under the symbol “TENX”.
Caution Regarding Forward-Looking Statements
Except for historical information, all of the statements, expectations and assumptions contained in this press release are forward-looking statements. These forward-looking statements may include information concerning possible or projected future business operations. Actual results might differ materially from those explicit or implicit in the forward-looking statements. Important factors that could cause actual results to differ materially include: our ability to maintain our culture and recruit, integrate and retain qualified personnel and advisors, including on our Board of Directors; risks related to our business strategy, including the prioritization and development of product candidates; risks of our clinical trials, including, but not limited to, the timing, delays, costs, design, initiation, enrollment, and results of such trials; any delays in regulatory review and approval of product candidates in development; reliance on third parties, including Orion Corporation, our manufacturers and CROs; risks regarding the formulation, production, marketing, customer acceptance and clinical utility of our product candidates; our estimates regarding the potential market opportunity for our product candidates; the potential advantages of our product candidates; risks associated with our cash needs; our competitive position; intellectual property risks; volatility and uncertainty in the global economy and financial markets in light of the possibility of pandemics, global financial and geopolitical uncertainties, including in the Middle East and the Russian invasion of and war against the country of Ukraine; changes in legal, regulatory and legislative environments in the markets in which we operate and the impact of these changes on our ability to obtain regulatory approval for our products; and other risks and uncertainties set forth from time to time in our SEC filings. Tenax Therapeutics assumes no obligation and does not intend to update these forward-looking statements except as required by law.
Contacts
Investor Contact:
John Fraunces
Managing Director
LifeSci Advisors, LLC
C: 917-355-2395
jfraunces@lifesciadvisors.com
or
Brian Mullen
LifeSci Advisors, LLC
C: 203-461-1175
bmullen@lifesciadvisors.com
FAQ
When is Tenax Therapeutics (TENX) presenting at the Guggenheim SMID Cap Biotech Conference 2025?
What type of presentation will TENX deliver at the Guggenheim Biotech Conference?
How can investors access TENX's presentation at the Guggenheim Conference?
Will TENX management be available for individual investor meetings at the Guggenheim Conference?
What is the current development stage of Tenax Therapeutics (TENX)?
